Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
Vaxart, Inc. Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024...
Quarter
MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes
Completion of enrollment in the European Phase 3 clinical trial ARES designed to evaluate efficacy and safety of MaaT013 in...
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Cue Biopharma, Inc.BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel...
Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
ADI-001 autoimmune clinical development expanded beyond lupus nephritis (LN) to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil...
Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results
Absci CorporationReleased results from non-human primate studies for ABS-101, demonstrating 2-3x extended half-life as compared to antibodies in clinical developmentEntered...
